Viewing Study NCT02254018


Ignite Creation Date: 2025-12-25 @ 4:42 AM
Ignite Modification Date: 2026-03-15 @ 2:17 AM
Study NCT ID: NCT02254018
Status: COMPLETED
Last Update Posted: 2023-10-24
First Post: 2014-09-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
Sponsor: Boehringer Ingelheim
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module